Axsome Therapeutics Inc (AXSM) concluded trading on Thursday at a closing price of $104.46, with 0.42 million shares of worth about $44.0 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 20.86% during that period and on April 17, 2025 the price saw a loss of about -0.01%. Currently the company’s common shares owned by public are about 48.67M shares, out of which, 40.08M shares are available for trading.
Stock saw a price change of 9.21% in past 5 days and over the past one month there was a price change of -17.03%. Year-to-date (YTD), AXSM shares are showing a performance of 23.46% which increased to 51.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $64.11 but also hit the highest price of $139.13 during that period. The average intraday trading volume for Axsome Therapeutics Inc shares is 924.59K. The stock is currently trading -4.53% below its 20-day simple moving average (SMA20), while that difference is down -12.18% for SMA50 and it goes to 6.80% higher than SMA200.
Axsome Therapeutics Inc (NASDAQ: AXSM) currently have 48.67M outstanding shares and institutions hold larger chunk of about 78.96% of that.
The stock has a current market capitalization of $5.09B and its 3Y-monthly beta is at 0.50. It has posted earnings per share of -$6.00 in the same period. It has Quick Ratio of 2.04 while making debt-to-equity ratio of 3.56. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AXSM, volatility over the week remained 3.68% while standing at 5.37% over the month.
Stock’s fiscal year EPS is expected to rise by 47.22% while it is estimated to increase by 171.61% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on April 07, 2025 offering a Buy rating for the stock and assigned a target price of $200 to it. Coverage by Deutsche Bank stated Axsome Therapeutics Inc (AXSM) stock as a Buy in their note to investors on February 11, 2025, suggesting a price target of $176 for the stock. On December 31, 2024, Mizuho Reiterated their recommendations, while on September 03, 2024, Wells Fargo Initiated their ratings for the stock with a price target of $140. Stock get a Buy rating from BofA Securities on August 06, 2024.
